Fintel reports that on July 27, 2025, Barclays downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Fintel reports that on July 29, 2025, JP Morgan upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

Sarepta (SRPT) paused shipments of its top-selling gene therapy drug after the US Food and Drug Administration (FDA) raised ...

Arrowhead Pharmaceuticals (ARWR) stock gains as company reassures investors about financial obligations required from Sarepta ...